Overview
- A state filing and a federal WARN notice show 247 Massachusetts roles at 500 Kendall St. will be cut, with 387 additional jobs affected in other U.S. states.
- The reductions follow a March 25 board decision targeting about JPY 200 billion, or roughly $1.25 billion, in yearly savings by fiscal 2028.
- Takeda says the restructuring will simplify operations and move resources to late-stage medicines, including planned launches for oveporexton, rusfertide, and zasocitinib, with support offered for internal job moves.
- Hiring continues with about 700 open positions, including nearly 300 in Massachusetts, according to the company.
- This step extends earlier pullbacks that included 2024 Massachusetts layoffs and cuts after ending cell therapy work, alongside a Cambridge footprint shift with large space subleases and a new R&D hub planned at 585 Kendall.